^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BMS-986353

i
Other names: CD19-NEX-T, BMS-986353, CC-97540, NEX T CD19, CD19 NEX T
Associations
Company:
BMS
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
6ms
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=24, Completed, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Completed | N=80 --> 24 | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • BMS-986353
8ms
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis (clinicaltrials.gov)
P1, N=98, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Feb 2027 --> Jul 2027 | Trial primary completion date: Feb 2027 --> Jul 2027
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • BMS-986353
8ms
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (clinicaltrials.gov)
P1, N=129, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=43 --> 129
Enrollment change • CAR T-Cell Therapy
|
cyclophosphamide • fludarabine IV • BMS-986353
9ms
Enrollment open
|
cyclophosphamide • fludarabine IV • BMS-986353
9ms
A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
P1, N=43, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Feb 2028 --> Nov 2027 | Trial primary completion date: Feb 2028 --> Nov 2027
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • BMS-986353
10ms
New P1 trial
|
cyclophosphamide • fludarabine IV • BMS-986353
2years
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=80, Active, not recruiting, Juno Therapeutics, a Subsidiary of Celgene | Recruiting --> Active, not recruiting
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • BMS-986353
2years
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=80, Recruiting, Juno Therapeutics, a Subsidiary of Celgene | Trial completion date: Jan 2025 --> Jun 2024 | Trial primary completion date: Jan 2025 --> Jun 2024
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • BMS-986353
over4years
Clinical • Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
BMS-986353
almost5years
Clinical • Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
BMS-986353